NCT02721641 - A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Neoplasms

Interventions

DRUG

Herceptin

Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.

Trial Locations (41)

1023

Auckland

1090

Brussels

1122

Budapest

2170

Liverpool

2298

Waratah

3010

Alicante

3052

Parkville

3065

Fitzroy

3220

Geelong

4006

Brisbane

4032

Debrecen

4066

Brisbane

11000

Belgrade

12203

Berlin

13273

Marseille

20246

Hamburg

23538

Lübeck

37075

Göttingen

54290

Trier

69120

Heidelberg

80637

München

81377

München

100021

Beijing

100142

Beijing

115478

Moscow

197758

Saint Petersburg

426009

Izhevsk

5262100

Ramat Gan

01010

Guatemala City

0832-00752

Panama City

80-214

Gdansk

1099-023

Lisbon

463-802

Bundang City

03080

Seoul

120-752

Seoul

138-736

Seoul

08035

Barcelona

EH4 2XU

Edinburgh

G12 0YN

Glasgow

SE1 9RT

London

NG5 1PB

Nottingham

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY